1. Volume 71, Issue 12, Pages 1302-1309 (June 2007)
Polyomavirus-associated nephropathy risk in kidney transplants: the influence of recipient age and donor gender 
H.-A. Khamash, H.-M. Wadei, A.-S. Mahale, T.-S. Larson, M.-D. Stegall, F.-G. Cosio, M.-D. Griffin 
Kidney International 
Volume 71, Issue 12, Pages (June 2007)
DOI: /sj.ki
Copyright © 2007 International Society of Nephrology Terms and Conditions

2. Figure 1
The incidence of PVAN among recent KTx recipients. Kaplan–Meier curves are shown for (a). The cumulative occurrence of biopsy-proven PVAN among all 1027 patients receiving KTxs at Mayo Clinic between January 2000 and September 2004 and followed for up to 48 months post-transplantation. Cumulative occurrence of cases diagnosed by surveillance biopsy and non-surveillance biopsy is also shown. (b) KTx recipients managed with thymoglobulin compared with anti-IL2 receptor antibody (anti-CD25). (c). KTx recipients managed with tacrolimus, sirolimus, or cyclosporine as primary oral immunosuppressive agent. For (b) and (c) the number of KTx recipients in each subgroup at 0 months post-transplant is shown. There were no statistically significant differences for PVAN incidence among the subgroups analyzed.
Kidney International  , DOI: ( /sj.ki )
Copyright © 2007 International Society of Nephrology Terms and Conditions

3. Figure 2
Histological characteristics of surveillance and non-surveillance biopsies diagnostic of PVAN among the study cohort. (a) Results for the sum of acute tubulointerstitial abnormalities (Banff '97 i+t scores) and chronic tubulointerstitial abnormalities (Banff '97 ci+ct scores) on PVAN diagnostic biopsies are represented graphically for cases diagnosed by surveillance biopsy (surv.) or by non-surveillance biopsy (non-surv). Results are presented for i+t and ci+ct as the proportions of each subgroup with no abnormality (combined score 0), mild abnormality (combined score=1 or 2), moderate abnormality (combined score=3 or 4), or severe abnormality (combined score >4). (b) Results for Drachenberg grading (A, B, or C) of PVAN diagnostic biopsies are represented graphically for cases diagnosed by surveillance biopsy (surv.) or by non-surveillance biopsy (non-surv.). The P-values shown are the result of Fisher exact tests of combined Banff '97 score and Drachenberg grade distributions between surv. vs non-surv.
Kidney International  , DOI: ( /sj.ki )
Copyright © 2007 International Society of Nephrology Terms and Conditions

4. Figure 3
Graft survival for KTx recipients diagnosed with PVAN by surveillance biopsy and non-surveillance biopsy. Kaplan–Meier curves representing the rates of death-censored renal allograft survival (defined as ‘return to dialysis or re-transplantation’) from the time of transplantation to 48 months post-KTx are shown for recipients diagnosed with PVAN by surveillance biopsy (n=40) or by non-surveillance biopsy (n=34). P<0.01 for surveillance vs non-surveillance.
Kidney International  , DOI: ( /sj.ki )
Copyright © 2007 International Society of Nephrology Terms and Conditions

5. Figure 4
Risk of PVAN among five recipient age cohorts. Kaplan–Meier plots of the cumulative incidence of PVAN in recipients classified according to their age at the time of transplant as indicated in the figure margin (log rank=0.03). Comparisons among groups are indicated in the results section of the manuscript.
Kidney International  , DOI: ( /sj.ki )
Copyright © 2007 International Society of Nephrology Terms and Conditions

6. Figure 5
The incidence of PVAN among recipients of female donor compared to male donor kidneys. Kaplan–Meier curves are shown of the cumulative occurrence of biopsy-proven PVAN among patients receiving KTxs from female donors compared with male donors during the first 48 months post-transplant. There was a significantly higher incidence of PVAN among recipients of female kidneys (log rank=0.016).
Kidney International  , DOI: ( /sj.ki )
Copyright © 2007 International Society of Nephrology Terms and Conditions